SEP 09, 2015 09:00 AM PDT

WEBINAR: Clinically actionable gene fusions, CNVs and SNVs detected by NGS-based comprehensive profiling

SPONSORED BY: Archer DX, Archer DX
Speakers
  • Pathologist, Massachusetts General Hospital
    Biography
      Dr. Iafrate, a board-certified pathologist at Massachusetts General Hospital. He joined the hospital staff in 2005 and oversees the Center for Integrated Diagnostics (CID), which provides rapid personalized genomic testing to help inform cancer treatment decisions for patients. His lab focuses on genetic fingerprints guiding novel targeted cancer therapies. His research pioneered SNAPSHOT, a targeted genotyping assay recognizing over 100 common mutations in cancers. His lab has also been highly involved in the development of diagnostics for ALK- and ROS1-positive lung cancers indicative of crizotinib efficacy.

      Prior to working for Massachusetts General Hospital and Harvard University, Dr. Iafrate received his MD and PhD from State University of New York at Stony Brook and subsequently trained at Brigham and Women's Hospital for Anatomic and Molecular Genetic Pathology. His pivotal post-doctoral work elucidated a novel mechanism behind copy number variations (CNVs).

    Abstract:
    DATE: September 9, 2015
    TIME: 9:00am PDT, 12:00PM EDT

    Driver mutations are causally implicated in tumorigenesis and disease progression, and they are defined by molecular abnormalities such as gene fusions, copy number variations (CNVs), single-nucleotide variants (SNVs) and insertions/deletions (indels). Driver mutations vary by gene and cancer type, and the ability to accurately, rapidly and economically characterize all of the driver mutations in a single sample in a clinical setting has been untenable.

    Anchored Multiplex PCR (AMP™) is a target enrichment chemistry for next-generation sequencing (NGS). AMP is used by Archer FusionPlex assays to detect known and novel gene fusions, SNVs and indels from RNA and by Archer VariantPlex assays to detect CNVs, SNVs and indels from DNA.

    In this webinar, Dr. Iafrate outlines the limitations of current methods of mutation detection and shares data demonstrating the effective use of AMP chemistry for multiplex NGS-based mutation calling in the clinic.

    Dr. Iafrate also describes the concomitant use of AMP-based assays using RNA and DNA from a single sample, respectively, to generate a comprehensive tumor mutation profile with minimal sample input.


    Objectives:
    1. Describe the limitations of detecting mutations using standard molecular pathology
    2. Demonstrate accurate multiplex mutation calling using AMP chemistry
    3. Introduce comprehensive tumor mutation profiling from a single sample

    Show Resources
    You May Also Like
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    AUG 16, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 16, 2018 08:00 AM PDT
    DATE: August, 16, 2018TIME: 08:00AM PDTThis webinar will review recent advancements in the application of next-generation sequencing of T cell receptor beta (TCRB) chain repertoires towards...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    JUN 05, 2018 06:30 AM PDT
    C.E. CREDITS
    JUN 05, 2018 06:30 AM PDT
    DATE: June 5, 2018TIME: 06:30AM PDT, 3:30PM CEST Viscous liquids are a challenge in every lab that deals with them. Depending on how viscous a liquid is, pipetting is either...
    Loading Comments...